The same results were maintained at the end of 1 year. Patients were asked to fill a self-assessment questionnaire.Īt the end of 6 months, improvements in mid face and lower face were reported in 93% patients by blinded reviewers and 85% patients found the results to be satisfactory. Photographs were taken for detailed facial evaluation. Investigators Global Aesthetic Improvement Scales Scores and Patients Global Aesthetic Improvement Scales Scores were used for analysis at 30 days, 60 days, 3 months, 6 months, and 1 year. All patients were evaluated for allergic reactions and side effects like scarring and nerve/muscle dysfunction. The subjects were treated using Ulthera 3.0 mm probes which targets deep dermis and 4.5 mm, which targets the superficial muscular aponeurotic system. This study enrolled 50 adult patients of Indian ethnicity who opted for correction of mid face and lower face sagging by Ulthera. It employs micro-focused ultrasound to cause discrete focal heating of the dermis and stimulates neocollagenesis and elastin remodeling. Intense focused ultrasound, known as the Ulthera System (Ulthera Inc., Mesa, AZ, USA), was designed to correct this process. While the same LIFU treatment shows no obvious damage to cells, as proved by the live/dead experiment, showing that 90% of cells remain alive.The changes in the mid face and lower face are among the most prominent features of the aging process.

Most PAH/PSS/SiO 2 capsules in B50 rat neuronal cells can be ruptured and release rhodamine B (Rh-B) into the cytosol within only 30 s of 0.75 W cm −2 LIFU treatment, as demonstrated by the CLSM results. The release is achieved by a composite poly(allylamine hydrochloride) (PAH)/poly-(sodium 4-styrenesulfonate) (PSS)/SiO 2 microcapsules which are highly sensitive to LIFU and can be effectively broken by weak cavitation effects. Here, low intensity focused ultrasound (LIFU) for controlled quick intracellular release of small molecules ( M w ≤ 1000 Da) without acute cell damage is demonstrated. Non-ablative focused ultrasound assisted chemotherapy could open a new avenue for the development of cancer therapy technology. Focused ultrasound (FU) is in demand for clinical cancer therapy, but the possible thermal injury to the normal peripheral tissues limits the usage of the ablative FU for tumors with a large size therefore research efforts have been made to minimize the possible side effects induced by the FU treatment.

Micro focus ultrasound